Direct thrombin inhibitors

被引：8

作者：

Chen M.S. ^{[1
]}

Lincoff A.M. ^{[1
]}

机构：

[1] Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, OH 44195

来源：

Current Cardiology Reports | 2005年 / 7卷 / 4期

关键词：

Percutaneous Coronary Intervention; Abciximab; Primary Percutaneous Coronary Intervention; Bivalirudin; Direct Thrombin Inhibitor;

D O I：

10.1007/s11886-005-0046-y

中图分类号：

学科分类号：

摘要：

Direct thrombin inhibitors (DTIs) are a new class of therapeutics possessing theoretic advantages over unfractionated heparin (UFH). In contrast to UFH, DTIs do not activate platelets, have no circulating inhibitors, and bind to both free and clot-bound thrombin. These theoretical advantages have spurred clinical trials investigating DTIs in a variety of cardiovascular indications. Currently, the major role for DTIs in cardiology is as an adjunct during percutaneous coronary intervention (PCI). Such h role stems from the results of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 randomized trial, in which bivalirudin with provisional abciximab was demonstrated to be equivalent to UFH plus planned abciximab with respect to ischemic endpoints, while being associated with less bleeding. Ongoing clinical trials will define the role of bivalirudin as an adjunct to primary PCI for ST-segment elevation myocardial infarction and in non-ST segment elevation acute coronary syndrome as an adjunct to an early invasive strategy. Copyright © 2005 by Current Science Inc.

引用

页码：255 / 259

页数：4

共 21 条

[1]

Serruys P.W., Herrman J.P., Simon R., Et al., A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty, N. Engl. J. Med., 333, pp. 757-763, (1995)

[2]

Bittl J.A., Strony J., Brinker J.A., Et al., Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina, N. Engl. J. Med., 333, pp. 764-769, (1995)

[3]

Bittl J.A., Chaitman B.R., Feit F., Et al., Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study, Am. Heart J., 142, pp. 952-959, (2001)

[4]

Lincoff A.M., Kleiman N.S., Kottke-Marchant K., Et al., Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET), Am. Heart J., 143, pp. 847-853, (2002)

[5]

Lincoff A.M., Bittl J.A., Kleiman N.S., Et al., Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial), Am. J. Cardiol., 93, pp. 1092-1096, (2004)

[6]

Lincoff A.M., Bittl J.A., Harrington R.A., Et al., Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial, JAMA, 289, pp. 853-863, (2003)

[7]

Lincoff A.M., Kleiman N.S., Kereiakes D.J., Et al., Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial, JAMA, 292, pp. 696-703, (2004)

[8]

Cohen D.J., Lincoff A.M., Lavelle T.A., Et al., Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial, J. Am. Coll. Cardiol., 44, pp. 1792-1800, (2004)

[9]

Dangas G.D., Lasic Z., Mehran R., Et al., Bivalirudin is a safe replacement to heparin during percutaneous coronary intervention with drug-eluting stents: Final results of the multicenter ADEST study, Am. J. Cardiol., 94, SUPPL. 6A, (2004)

[10]

A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes, N. Engl. J. Med., 335, pp. 775-782, (1996)

← 1 2 3 →